does tirzepatide cause osteoporosis Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites Frontiers | Bone mineral density

While the medication can be costly without insurance, Klinic's prior authorization support and guidance with insurance coverage can significantly lower expense barriers

There are some real medical risks to consider as well

Geography Analysis North America Anti-obesity Drugs Market North America dominated with 39.53% of the anti-obesity drugs market in 2025, buoyed by obesity prevalence surpassing 41% of adults and expanding Medicare Part D coverage that raised the eligible pool by 15 million beneficiaries

Results typically last up to 12 months before the filler naturally breaks down in the body

Experts say a less expensive version of these GLP-1 medications would give more people access to these effective weight-loss drugs